The chemical class of FADS2 activators encompasses a diverse range of compounds that can enhance the activity of the enzyme Fatty Acid Desaturase 2 (FADS2). FADS2 is crucial in the metabolic pathways of polyunsaturated fatty acids (PUFAs), playing a key role in the introduction of double bonds in fatty acids. This enzyme is integral to the biosynthesis of long-chain PUFAs, including arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. The activation of FADS2, therefore, has significant implications for the metabolism and availability of these essential fatty acids. FADS2 activators can be of various natures, including certain fatty acids themselves, compounds that modify gene expression, and molecules that influence the enzyme's regulatory mechanisms.
These activators often function at the molecular level by either directly interacting with the enzyme or by altering the expression of the FADS2 gene. Some activators might bind to the active site or allosteric sites of the enzyme, inducing conformational changes that enhance enzyme activity. Others might influence the transcriptional machinery, leading to increased production of the FADS2 enzyme. Additionally, certain activators might affect the enzyme's stability, protecting it from degradation, or they may influence the lipid environment in which FADS2 operates, thereby facilitating its activity. The interaction of FADS2 activators with the enzyme is a complex process and can depend on various factors, including the cellular context, the presence of cofactors, and the overall metabolic state of the cell. Understanding the mechanisms by which these activators function is key to comprehending their role in fatty acid metabolism.
SEE ALSO...
Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $71.00 $202.00 $284.00 | 9 | |
C75 is an inhibitor of fatty acid synthase (FASN). Inhibition of FASN by C75 can indirectly activate FADS2 by affecting the cellular balance of fatty acid synthesis and degradation pathways, leading to a potential compensatory upregulation of FADS2 to maintain lipid homeostasis. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone is a PPARγ agonist that activates peroxisome proliferator-activated receptor gamma (PPARγ). Through PPARγ activation, Rosiglitazone influences lipid metabolism and may indirectly impact FADS2 expression by modulating the transcriptional regulation of fatty acid synthesis genes. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 is a direct AMPK activator that stimulates AMPK phosphorylation. By directly activating AMPK, A769662 can influence cellular energy sensing and metabolism, potentially leading to indirect FADS2 activation by modulating pathways related to lipid metabolism and fatty acid synthesis. | ||||||
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $190.00 $815.00 | 11 | |
GW0742 is a PPARβ/δ agonist that activates peroxisome proliferator-activated receptor beta/delta (PPARβ/δ). Through PPARβ/δ activation, GW0742 can modulate lipid metabolism, potentially indirectly impacting FADS2 expression by influencing the transcriptional regulation of fatty acid synthesis genes. | ||||||